TCTAP C-026 Simultaneous Double Vessel Stent Thrombosis
نویسندگان
چکیده
منابع مشابه
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism
Clopidogrel resistance from CYP2C19 polymorphism has been associated with stent thrombosis in patients undergoing percutaneous coronary intervention with drug-eluting stents. We present a case of a 76-year-old male who received drug-eluting stents to the right coronary artery and left anterior descending artery for non-ST elevation myocardial infarction and was discharged on dual antiplatelet t...
متن کاملTriple, simultaneous, very late coronary stent thrombosis.
Coronary artery stent thrombosis is an uncommon but potentially catastrophic complication. The risk of very late stent thrombosis (VLST) raises important safety issues regarding the first generation of drug-eluting stents (DES). Although several complex mechanisms for VLST have been suggested and various predictors have been described, its pathophysiology is not completely understood and it is ...
متن کاملLost contact with vessel wall, signed contract with stent thrombosis?
Drug-eluting stents (DES) represent the most successful approach in preventing restenosis after percutaneous coronary interventions (PCIs). Many believe, however, that reduction of neointima formation is associated with a worrisome side effect, an increased risk of very late stent thrombosis, at least as observed with early DES technologies. An adverse vessel wall reaction to two DES components...
متن کاملSimultaneous Multi-Vessel Subacute Stent Thromboses in Zotarolimus-Eluting Stents
Despite its low incidence, stent thrombosis (ST) is one of the most dreaded complications of percutaneous coronary intervention. Endeavor (Medtronics Europe SA) is a new zotarolimus-eluting stent (ZES) with a favorable safety profile that was reported in early and ongoing trials. However, few lethal stent thromboses related to this new drug eluting stent (DES) have been reported. We experienced...
متن کاملSimultaneous double-culprit in-stent thrombosis. Who is the guilty prisoner behind bars: drug-eluting stent, bare-metal stent, or indication for treatment?
BACKGROUND The intrinsic thrombogeneity of stents was the historic limitation to their usage during the early phases of stenting. The risk of stent thrombosis has been minimized by the widespread use of platelet antiaggregation. Nowadays, the risk of subacute stent thrombosis is around 1%. Thrombotic risk depends on several factors, such as type of stent, complexity of lesion, and clinical pict...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2019
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2019.03.213